{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:59:28Z","timestamp":1783749568724,"version":"3.55.0"},"reference-count":38,"publisher":"Bentham Science Publishers Ltd.","issue":"35","funder":[{"DOI":"10.13039\/501100004564","name":"Ministry of Education, Science and Technological Development, Republic of Serbia","doi-asserted-by":"publisher","award":["41012"],"award-info":[{"award-number":["41012"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,12,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Resveratrol was demonstrated to act as partial agonist of PPAR-\u03b3 receptor, which opens\nup the possibility for its use in the treatment of metabolic disorders. Considering the poor bioavailability of resveratrol,\nparticularly due to its low aqueous solubility, we aimed to identify analogues of resveratrol with improved\npharmacokinetic properties and higher binding affinities towards PPAR-\u03b3.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>3D structures of resveratrol and its analogues were retrieved from ZINC database, while PPAR-\u03b3 structure\nwas obtained from Protein Data Bank. Docking studies were performed using Molegro Virtual Docker software.\nMolecular descriptors relevant to pharmacokinetics were calculated from ligand structures using VolSurf+\nsoftware.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Using structural similarity search method, 56 analogues of resveratrol were identified and subjected to\ndocking analyses. Binding energies were ranged from -136.69 to -90.89 kcal\/mol, with 16 analogues having\nhigher affinities towards PPAR-\u03b3 in comparison to resveratrol. From the calculated values of SOLY descriptor,\n23 studied compounds were shown to be more soluble in water than resveratrol. However, only two tetrahydroxy\nstilbene derivatives, piceatannol and oxyresveratrol, had both better solubility and affinity towards PPAR-\u03b3.\nThese compounds also had more favorable ADME profile, since they were shown to be more metabolically stable\nand wider distributed in body than resveratrol.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Piceatannol and oxyresveratrol should be considered as potential lead compounds for further drug\ndevelopment. Although experimental validation of obtained in silico results is required, this work can be considered\nas a step toward the discovery of new natural and safe drugs in treatment of metabolic disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666191029095252","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T06:33:10Z","timestamp":1572417190000},"page":"3776-3783","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In silico Discovery of Resveratrol Analogues as Potential Agents in Treatment of Metabolic Disorders"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-5830","authenticated-orcid":true,"given":"Neboj\u0161a","family":"Pavlovi\u0107","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-0666","authenticated-orcid":true,"given":"Maja","family":"\u0110ani\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-3182","authenticated-orcid":true,"given":"Bojan","family":"Stanimirov","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2850-6375","authenticated-orcid":true,"given":"Svetlana","family":"Golo\u010dorbin-Kon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-3473","authenticated-orcid":true,"given":"Karmen","family":"Stankov","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8354-3868","authenticated-orcid":true,"given":"Mladena","family":"Lali\u0107-Popovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-0624","authenticated-orcid":true,"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.phrs.2009.03.020","volume":"60","author":"Huang T.H.W.","year":"2009","unstructured":"Huang T.H.W.; Teoh A.W.; Lin B.L.; Lin D.S.H.; Roufogalis B.; The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 2009,60(3),195-206","journal-title":"Pharmacol Res"},{"key":"ref=2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/549627","volume":"2013","author":"Monsalve F.A.","year":"2013","unstructured":"Monsalve F.A.; Pyarasani R.D.; Delgado-Lopez F.; Moore-Carrasco R.; Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013,2013","journal-title":"Mediators Inflamm"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2174\/1381612823666161118145850","volume":"23","author":"Ivanova E.A.","year":"2017","unstructured":"Ivanova E.A.; Myasoedova V.A.; Melnichenko A.A.; Orekhov A.N.; Peroxisome Proliferator-Activated Receptor (PPAR) gamma agonists as therapeutic agents for cardiovascular disorders: focus on atherosclerosis. Curr Pharm Des 2017,23(7),1119-1124","journal-title":"Curr Pharm Des"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1042\/CS20080195","volume":"116","author":"Villacorta L.","year":"2009","unstructured":"Villacorta L.; Schopfer F.J.; Zhang J.; Freeman B.A.; Chen Y.E.; PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 2009,116(3),205-218","journal-title":"Clin Sci (Lond)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jsbmb.2011.01.005","volume":"127","author":"Janesick A.","year":"2011","unstructured":"Janesick A.; Blumberg B.; Minireview: PPAR\u03b3 as the target of obesogens. J Steroid Biochem Mol Biol 2011,127(1-2),4-8","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"Soccio R.E.","year":"2014","unstructured":"Soccio R.E.; Chen E.R.; Lazar M.A.; Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 2014,20(4),573-591","journal-title":"Cell Metab"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","volume":"92","author":"Wang L.","year":"2014","unstructured":"Wang L.; Waltenberger B.; Pferschy-Wenzig E.M.; Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review. Biochem Pharmacol 2014,92(1),73-89","journal-title":"Biochem Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/cbic.201300754","volume":"15","author":"Calleri E.","year":"2014","unstructured":"Calleri E.; Pochetti G.; Dossou K.S.S.; Resveratrol and its metabolites bind to PPARs. ChemBioChem 2014,15(8),1154-1160","journal-title":"ChemBioChem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neulet.2003.09.001","volume":"352","author":"Inoue H.","year":"2003","unstructured":"Inoue H.; Jiang X.F.; Katayama T.; Osada S.; Umesono K.; Namura S.; Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor \u03b1 in mice. Neurosci Lett 2003,352(3),203-206","journal-title":"Neurosci Lett"},{"key":"ref=10","first-page":"1","volume":"21","author":"Murtaza G.","year":"2013","unstructured":"Murtaza G.; Latif U.; Najam-Ul-Haq M.; Resveratrol: An active natural compound in red wines for health. Yao Wu Shi Pin Fen Xi 2013,21,1-12","journal-title":"Yao Wu Shi Pin Fen Xi"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10311-017-0660-0","volume":"16","author":"Arora D.","year":"2018","unstructured":"Arora D.; Jaglan S.; Therapeutic applications of resveratrol nanoformulations. Environ Chem Lett 2018,16,35-41","journal-title":"Environ Chem Lett"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4284","DOI":"10.1039\/C7FO01300K","volume":"8","author":"Rauf A.","year":"2017","unstructured":"Rauf A.; Imran M.; Suleria H.A.R.; Ahmad B.; Peters D.G.; Mubarak M.S.; A comprehensive review of the health perspectives of resveratrol. Food Funct 2017,8(12),4284-4305","journal-title":"Food Funct"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/NHA-170035","volume":"4","author":"Wahl D.","year":"2018","unstructured":"Wahl D.; Bernier M.; Simpson S.J.; de Cabo R.; Le Couteur D.G.; Future directions of resveratrol research. Nutr Healthy Aging 2018,4(4),287-290","journal-title":"Nutr Healthy Aging"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1017\/S0007114511000316","volume":"106","author":"Brasny\u00f3 P.","year":"2011","unstructured":"Brasny\u00f3 P.; Moln\u00e1r G.A.; Moh\u00e1s M.; Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011,106(3),383-389","journal-title":"Br J Nutr"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tifs.2014.05.003","volume":"38","author":"Davidov-Pardo G.","year":"2014","unstructured":"Davidov-Pardo G.; McClements D.J.; Resveratrol encapsulation: designing delivery systems to overcome solubility, stability and bioavailability issues. Trends Food Sci Technol 2014,38,88-103","journal-title":"Trends Food Sci Technol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2011.09.083","volume":"158","author":"Amri A.","year":"2012","unstructured":"Amri A.; Chaumeil J.C.; Sfar S.; Charrueau C.; Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release 2012,158(2),182-193","journal-title":"J Control Release"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.hermed.2017.09.002","volume":"11","author":"de Vries K.","year":"2018","unstructured":"de Vries K.; Strydom M.; Steenkamp V.; Bioavailability of resveratrol: possibilities for enhancement. J Herb Med 2018,11,71-77","journal-title":"J Herb Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2174\/092986712799945085","volume":"19","author":"Neves A.R.","year":"2012","unstructured":"Neves A.R.; L\u00facio M.; Lima J.L.C.; Reis S.; Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Curr Med Chem 2012,19(11),1663-1681","journal-title":"Curr Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/nu9111188","volume":"9","author":"Nawaz W.","year":"2017","unstructured":"Nawaz W.; Zhou Z.; Deng S.; Therapeutic versatility of resveratrol derivatives. Nutrients 2017,9(11),9","journal-title":"Nutrients"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/861238","volume":"2010","author":"Lewis S.N.","year":"2010","unstructured":"Lewis S.N.; Bassaganya-Riera J.; Bevan D.R.; Review article: virtual screening as a technique for PPAR modulator discovery. PPAR Res 2010,2010","journal-title":"PPAR Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1021\/jm051129s","volume":"49","author":"Lu I.L.","year":"2006","unstructured":"Lu I.L.; Huang C.F.; Peng Y.H.; Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro\/in vivo biological activities. J Med Chem 2006,49(9),2703-2712","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"Berman H.M.","year":"2000","unstructured":"Berman H.M.; Westbrook J.; Feng Z.; The protein data bank. Nucleic Acids Res 2000,28(1),235-242","journal-title":"Nucleic Acids Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1021\/ci3001277","volume":"52","author":"Irwin J.J.","year":"2012","unstructured":"Irwin J.J.; Sterling T.; Mysinger M.M.; Bolstad E.S.; Coleman R.G.; ZINC: A free tool to discover chemistry for biology. J Chem Inf Model 2012,52(7),1757-1768","journal-title":"J Chem Inf Model"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1021\/jm051197e","volume":"49","author":"Thomsen R.","year":"2006","unstructured":"Thomsen R.; Christensen M.H.; MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006,49(11),3315-3321","journal-title":"J Med Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/15701808113109990044","volume":"11","author":"Singh S.P.","year":"2014","unstructured":"Singh S.P.; Konwar B.K.; Virtual screening and molecular descriptor analysis on dietary phytochemicals against heat shock protein 90 enzyme. Lett Drug Des Discov 2014,11,40-49","journal-title":"Lett Drug Des Discov"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/B978-012369520-8.50005-X","author":"Kerns E.H.","year":"2008","unstructured":"Kerns E.H.; Di L.;  Rules for Rapid Property Profiling from StructureDrug-like Properties: Concepts, Structure Design and Methods 2008,37-42","journal-title":"Rules for Rapid Property Profiling from StructureDrug-like Properties: Concepts, Structure Design and Methods"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2015.01.009","volume":"86","author":"Tian S.","year":"2015","unstructured":"Tian S.; Wang J.; Li Y.; Li D.; Xu L.; Hou T.; The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev 2015,86,2-10","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1016\/S0928-0987(00)00162-7","volume":"11","author":"Cruciani G.","year":"2000","unstructured":"Cruciani G.; Pastor M.; Guba W.; VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. Eur J Pharm Sci 2000,11(Suppl. 2),S29-S39","journal-title":"Eur J Pharm Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nchem.1243","volume":"4","author":"Bickerton G.R.","year":"2012","unstructured":"Bickerton G.R.; Paolini G.V.; Besnard J.; Muresan S.; Hopkins A.L.; Quantifying the chemical beauty of drugs. Nat Chem 2012,4(2),90-98","journal-title":"Nat Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3329\/bjp.v9i3.18915","volume":"9","author":"Selvaraj G.","year":"2014","unstructured":"Selvaraj G.; Kaliamurthi S.; Thirugnanasambandam R.; Molecular docking studies on potential PPAR-\u03b3 agonist from Rhizophora apiculata. Bangladesh J Pharmacol 2014,9,298-302","journal-title":"Bangladesh J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/qua.10575","volume":"93","author":"Xu X.Y.","year":"2003","unstructured":"Xu X.Y.; Cheng F.; Shen J.H.; Agonist-PPAR\u03b3 interactions: Molecular modeling study with docking approach. Int J Quantum Chem 2003,93,405-410","journal-title":"Int J Quantum Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/DDDT.S72794","volume":"9","author":"Mirza M.U.","year":"2014","unstructured":"Mirza M.U.; Mirza A.H.; Ghori N.U.; Ferdous S.; Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson\u2019s disease: a pharmacoinformatics study. Drug Des Devel Ther 2014,9,187-198","journal-title":"Drug Des Devel Ther"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13318-014-0234-5","volume":"41","author":"Rastogi H.","year":"2016","unstructured":"Rastogi H.; Jana S.; Evaluation of physicochemical properties and intestinal permeability of six dietary polyphenols in human intestinal colon adenocarcinoma Caco-2 cells. Eur J Drug Metab Pharmacokinet 2016,41(1),33-43","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mrrev.2011.11.001","volume":"750","author":"Piotrowska H.","year":"2012","unstructured":"Piotrowska H.; Kucinska M.; Murias M.; Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res 2012,750(1),60-82","journal-title":"Mutat Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/01635580903285072","volume":"61","author":"Youn J.","year":"2009","unstructured":"Youn J.; Lee J.S.; Na H.K.; Kundu J.K.; Surh Y.J.; Resveratrol and piceatannol inhibit iNOS expression and NF-kappaB activation in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 2009,61(6),847-854","journal-title":"Nutr Cancer"},{"key":"ref=36","first-page":"506","volume":"7","author":"Sangsen Y.","year":"2013","unstructured":"Sangsen Y.; Likhitwitayawuid K.; Sritularak B.; Wiwattanawongsa K.; Wiwattanapatapee R.; Novel solid lipid nanoparticles for oral delivery of oxyresveratrol: effect of the formulation parameters on the physicochemical properties and in vitro release. Int J Med Pharm Sci Eng 2013,7,506-513","journal-title":"Int J Med Pharm Sci Eng"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejphar.2012.01.036","volume":"680","author":"Weber J.T.","year":"2012","unstructured":"Weber J.T.; Lamont M.; Chibrikova L.; Potential neuroprotective effects of oxyresveratrol against traumatic injury. Eur J Pharmacol 2012,680(1-3),55-62","journal-title":"Eur J Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jff.2016.01.020","volume":"22","author":"Chen W.","year":"2016","unstructured":"Chen W.; Yeo S.C.M.; Elhennawy M.G.A.A.; Lin H.S.; Oxyresveratrol: A bioavailable dietary polyphenol. J Funct Foods 2016,22,122-131","journal-title":"J Funct Foods"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/176258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T07:58:28Z","timestamp":1578556708000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/176258\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,11]]},"references-count":38,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2019,12,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666191029095252","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}